JP2019176880A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019176880A5 JP2019176880A5 JP2019131862A JP2019131862A JP2019176880A5 JP 2019176880 A5 JP2019176880 A5 JP 2019176880A5 JP 2019131862 A JP2019131862 A JP 2019131862A JP 2019131862 A JP2019131862 A JP 2019131862A JP 2019176880 A5 JP2019176880 A5 JP 2019176880A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- several genes
- patients
- adaptive immune
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 claims description 26
- 230000004044 response Effects 0.000 claims description 22
- 230000004083 survival Effects 0.000 claims description 19
- 230000033289 adaptive immune response Effects 0.000 claims 10
- 230000001506 immunosuppresive Effects 0.000 claims 10
- 230000001747 exhibiting Effects 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000000259 anti-tumor Effects 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 102100019764 PDCD1 Human genes 0.000 description 24
- 108060007796 SPATA2 Proteins 0.000 description 24
- 238000002512 chemotherapy Methods 0.000 description 17
- 102100003283 CD3E Human genes 0.000 description 13
- 101700052503 CD3E Proteins 0.000 description 13
- 102100015249 VEGFA Human genes 0.000 description 13
- 101700068732 VEGFA Proteins 0.000 description 13
- 102100009641 CXCL10 Human genes 0.000 description 9
- 101710032181 CXCL10 Proteins 0.000 description 9
- 102100005310 CTLA4 Human genes 0.000 description 7
- 101700054183 CTLA4 Proteins 0.000 description 7
- 102100008191 CD8A Human genes 0.000 description 6
- 101700054655 CD8A Proteins 0.000 description 6
- 201000011231 colorectal cancer Diseases 0.000 description 6
- 102100012089 CD3G Human genes 0.000 description 5
- 101700026255 CD3G Proteins 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 102100016449 CCL5 Human genes 0.000 description 4
- 101700063377 CCL5 Proteins 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 102100004385 GZMH Human genes 0.000 description 3
- 101710014271 GZMH Proteins 0.000 description 3
- 102100012151 ITGAE Human genes 0.000 description 3
- 101710006585 ITGAE Proteins 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 102100013082 CD1A Human genes 0.000 description 2
- 101700015984 CD1A Proteins 0.000 description 2
- 102100009637 CXCL11 Human genes 0.000 description 2
- 101710032182 CXCL11 Proteins 0.000 description 2
- 102100009686 CXCL9 Human genes 0.000 description 2
- 101700052645 CXCL9 Proteins 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 206010025650 Malignant melanoma Diseases 0.000 description 2
- 241000282941 Rangifer tarandus Species 0.000 description 2
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 2
- 102000006381 STAT1 Transcription Factor Human genes 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 102100000546 CX3CL1 Human genes 0.000 description 1
- 101710027818 CX3CL1 Proteins 0.000 description 1
Description
図19は、後期卵巣癌患者の4つの部分集合についてのOSについてのカプランマイヤー曲線を示す。患者に化学療法を受けさせ、4つの部分集合の患者を分類した。完全応答を示す患者(CR)及び完全応答を示さない患者(IR)。各対は「Hi-Hi」患者の部分集合を含み、他の対は3つの他の患者群(その他)によって構成される。
図20は、後期卵巣癌患者の4つの部分集合についてのOSについてのカプランマイヤー曲線を示す。患者に化学療法を受けさせ、4つの部分集合の患者を分類した。完全応答を示す患者(CR)及び完全応答を示さない患者(IR)。各対は「Hi-Hi」患者の部分集合を含み、他の対は3つの他の患者群(その他)によって構成される。
Claims (6)
- i)ステージIVの固形癌の患者から得られた腫瘍サンプルにおいて、ヒト適応免疫応答を示す1つ又はいくつかの遺伝子の発現レベル及びヒト免疫抑制応答を示す1つ又はいくつかの遺伝子の発現レベルを決定する工程、
ii)工程i)で決定されたヒト適応免疫応答を示す1つ又はいくつかの遺伝子の発現レベル及びヒト免疫抑制応答を示す1つ又はいくつかの遺伝子の発現レベルを、ヒト適応免疫応答を示す1つ又はいくつかの遺伝子について予め決定された参照値及びヒト免疫抑制応答を示す1つ又はいくつかの遺伝子について予め決定された参照値と比較する工程(前記の予め決定された参照値は、前記遺伝子の発現レベル並びにカプランマイヤー曲線分析による患者の生存及び関連したログランクp値に従って、一団の癌患者を2つのグループに分別するように選択された)
iii)患者の適応免疫応答が良好(予め決定された参照値よりも高いレベル)又は不良(予め決定された参照値よりも低いレベル)かどうか、及び、免疫抑制応答が良好又は不良かどうかを結論付ける工程
を含む、ステージIVの固形癌の癌患者の抗腫瘍治療への応答性を評価するためのデータを提供するための方法であって、
前記ヒト適応免疫応答を示す1つ又はいくつかの遺伝子が、
前記ヒト免疫抑制応答を示す1つ又はいくつかの遺伝子が、
患者が前記良好な適応免疫応答及び前記良好な免疫抑制応答を有する場合に、抗腫瘍処置を受けるのに有利である、
方法。 - ヒト適応免疫応答を示す1つの遺伝子及びヒト免疫抑制応答を示す1つの遺伝子を、工程i)において使用する、請求項1に記載の方法。
- 請求項1から3のいずれか一項に記載の方法において、ヒト適応免疫応答を示す1つ又はいくつかの遺伝子の発現レベル及びヒト免疫抑制応答を示す1つ又はいくつかの遺伝子の発現レベルの決定の工程を実施するための、プライマー又はプローブとして使用される核酸又は抗体を含むキット。
- 前記核酸又は抗体が、前記適応免疫応答を示す1つ又はいくつかの遺伝子及び前記免疫抑制応答を示す1つ又はいくつかの遺伝子に特異的である、請求項4に記載のキット。
- 前記核酸が、請求項1又は2に記載の遺伝子に特異的な核酸から選択される、請求項4又は5に記載のキット。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12305975.0 | 2012-08-06 | ||
EP12305975 | 2012-08-06 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015525857A Division JP6559566B2 (ja) | 2012-08-06 | 2013-08-05 | 癌患者をスクリーニングするための方法及びキット |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019176880A JP2019176880A (ja) | 2019-10-17 |
JP2019176880A5 true JP2019176880A5 (ja) | 2021-05-06 |
JP6995091B2 JP6995091B2 (ja) | 2022-01-14 |
Family
ID=46762994
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015525857A Active JP6559566B2 (ja) | 2012-08-06 | 2013-08-05 | 癌患者をスクリーニングするための方法及びキット |
JP2019131862A Active JP6995091B2 (ja) | 2012-08-06 | 2019-07-17 | 癌患者をスクリーニングするための方法及びキット |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015525857A Active JP6559566B2 (ja) | 2012-08-06 | 2013-08-05 | 癌患者をスクリーニングするための方法及びキット |
Country Status (13)
Country | Link |
---|---|
US (2) | US20150218650A1 (ja) |
EP (2) | EP3470531A1 (ja) |
JP (2) | JP6559566B2 (ja) |
AU (1) | AU2013301609B2 (ja) |
CA (1) | CA2881389C (ja) |
DK (1) | DK2880180T3 (ja) |
ES (1) | ES2702722T3 (ja) |
LT (1) | LT2880180T (ja) |
PL (1) | PL2880180T3 (ja) |
PT (1) | PT2880180T (ja) |
SG (1) | SG11201500922RA (ja) |
TR (1) | TR201819211T4 (ja) |
WO (1) | WO2014023706A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108997498A (zh) | 2008-12-09 | 2018-12-14 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
ES2915849T3 (es) * | 2014-08-19 | 2022-06-27 | Nat Univ Corporation Okayama Univ | Combinación de agente bloqueante de factor inmunosupresor y fármaco antidiabético de biguanida para su uso en un método de prevención de la progresión, del tratamiento y/o de la prevención del cáncer |
WO2016109546A2 (en) * | 2014-12-30 | 2016-07-07 | Genentech, Inc. | Methods and compositions for prognosis and treatment of cancers |
AU2017261685B2 (en) * | 2016-05-09 | 2023-09-07 | Assistance Publique - Hôpitaux De Paris | Methods for classifying patients with a solid cancer |
ES2953595T3 (es) | 2017-03-01 | 2023-11-14 | Hoffmann La Roche | Procedimientos diagnósticos y terapéuticos para el cáncer |
JP6565093B1 (ja) | 2018-03-22 | 2019-08-28 | 住友電工ハードメタル株式会社 | 表面被覆切削工具およびその製造方法 |
US20220236276A1 (en) | 2019-06-03 | 2022-07-28 | Inserm (Institut National De La Santé Et De La Recherch Médicale | Methods for modulating a treatment regimen |
AU2020378280A1 (en) | 2019-11-07 | 2022-04-07 | Oncxerna Therapeutics, Inc. | Classification of tumor microenvironments |
GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
EP4172621A1 (en) | 2020-06-30 | 2023-05-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies |
US20230266322A1 (en) | 2020-06-30 | 2023-08-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery |
WO2023175366A1 (en) | 2022-03-17 | 2023-09-21 | Veracyte | Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4888278A (en) | 1985-10-22 | 1989-12-19 | University Of Massachusetts Medical Center | In-situ hybridization to detect nucleic acid sequences in morphologically intact cells |
US6280929B1 (en) | 1986-01-16 | 2001-08-28 | The Regents Of The University Of California | Method of detecting genetic translocations identified with chromosomal abnormalities |
US5447841A (en) | 1986-01-16 | 1995-09-05 | The Regents Of The Univ. Of California | Methods for chromosome-specific staining |
US5427932A (en) | 1991-04-09 | 1995-06-27 | Reagents Of The University Of California | Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using |
US5472842A (en) | 1993-10-06 | 1995-12-05 | The Regents Of The University Of California | Detection of amplified or deleted chromosomal regions |
US6942970B2 (en) | 2000-09-14 | 2005-09-13 | Zymed Laboratories, Inc. | Identifying subjects suitable for topoisomerase II inhibitor treatment |
JP2002363169A (ja) * | 2001-06-08 | 2002-12-18 | Fujiyakuhin Co Ltd | 抗腫瘍活性を有する複素環化合物 |
EP1664762A4 (en) * | 2003-09-03 | 2008-08-13 | Us Gov Health & Human Serv | METHODS OF IDENTIFICATION, DIAGNOSIS AND PREDICTION FOR LYMPHOMES SURVIVAL |
US20110152115A1 (en) * | 2003-09-03 | 2011-06-23 | The United States of America, as represented by the Secretary, Department of Health and | Methods for identifying, diagnosing, and predicting survival of lymphomas |
US20060246524A1 (en) | 2005-04-28 | 2006-11-02 | Christina Bauer | Nanoparticle conjugates |
ES2609919T3 (es) | 2005-04-28 | 2017-04-25 | Ventana Medical Systems, Inc. | Enzimas conjugados con anticuerpos mediante un conector de PEG heterobifuncional |
EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
ES2548518T3 (es) | 2005-11-23 | 2015-10-19 | Ventana Medical Systems, Inc. | Conjugado molecular |
US20110070582A1 (en) * | 2008-11-03 | 2011-03-24 | Source Precision Medicine, Inc. d/b/d Source MDX | Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects |
PL2619576T3 (pl) * | 2010-09-24 | 2021-07-05 | Niels Grabe | Środki i sposoby do prognozowania odpowiedzi na leczenie u pacjenta chorego na nowotwór złośliwy |
US20140018255A1 (en) * | 2011-01-11 | 2014-01-16 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for predicting the outcome of a cancer in a patient by analysing gene expression |
-
2013
- 2013-08-05 PT PT13745117T patent/PT2880180T/pt unknown
- 2013-08-05 EP EP18196198.8A patent/EP3470531A1/en not_active Withdrawn
- 2013-08-05 PL PL13745117T patent/PL2880180T3/pl unknown
- 2013-08-05 US US14/420,053 patent/US20150218650A1/en not_active Abandoned
- 2013-08-05 SG SG11201500922RA patent/SG11201500922RA/en unknown
- 2013-08-05 JP JP2015525857A patent/JP6559566B2/ja active Active
- 2013-08-05 WO PCT/EP2013/066425 patent/WO2014023706A1/en active Application Filing
- 2013-08-05 TR TR2018/19211T patent/TR201819211T4/tr unknown
- 2013-08-05 CA CA2881389A patent/CA2881389C/en active Active
- 2013-08-05 DK DK13745117.5T patent/DK2880180T3/en active
- 2013-08-05 AU AU2013301609A patent/AU2013301609B2/en active Active
- 2013-08-05 EP EP13745117.5A patent/EP2880180B1/en active Active
- 2013-08-05 LT LTEP13745117.5T patent/LT2880180T/lt unknown
- 2013-08-05 ES ES13745117T patent/ES2702722T3/es active Active
-
2019
- 2019-07-17 JP JP2019131862A patent/JP6995091B2/ja active Active
-
2020
- 2020-06-09 US US16/896,736 patent/US20200299784A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019176880A5 (ja) | ||
Chen et al. | Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy | |
Ferrari et al. | Molecular mechanisms, biomarkers and emerging therapies for chemotherapy resistant TNBC | |
Plitas et al. | Regulatory T cells exhibit distinct features in human breast cancer | |
Lim et al. | Single-cell analysis of circulating tumor cells: why heterogeneity matters | |
Anantharaman et al. | Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients | |
Johnson et al. | Phase II study of dasatinib in patients with advanced non–small-cell lung cancer | |
Gasch et al. | Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer | |
Li et al. | B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas | |
Guo et al. | TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma | |
Arisi et al. | Circulating tumor DNA in precision oncology and its applications in colorectal cancer | |
Sjöström et al. | Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors | |
WO2013033629A3 (en) | Methods and compositions for the treatment and diagnosis of colorectal cancer | |
Minami et al. | Pretreatment lung immune prognostic index is a prognostic marker of chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitor | |
Wang et al. | Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas | |
WO2015138769A1 (en) | Methods and compositions for assessing patients with non-small cell lung cancer | |
Jung et al. | Serum lactate dehydrogenase with a systemic inflammation score is useful for predicting response and survival in patients with newly diagnosed diffuse large B-cell lymphoma | |
JP2015530877A5 (ja) | ||
Zhang et al. | ITGAL as a prognostic biomarker correlated with immune infiltrates in gastric cancer | |
Lu et al. | Clinical significance and prognostic value of Nek2 protein expression in colon cancer | |
Turner et al. | Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer? | |
Cheng et al. | Systematic pan‐cancer analysis of KLRB1 with prognostic value and immunological activity across human tumors | |
Zarrabi et al. | Immune checkpoint inhibition in advanced non-clear cell renal cell carcinoma: leveraging success from clear cell histology into new opportunities | |
Bobrie et al. | Association of CD206 protein expression with immune infiltration and prognosis in patients with triple-negative breast cancer | |
Onieva et al. | High IGKC-expressing intratumoral plasma cells predict response to immune checkpoint blockade |